Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedman, H. S.
Right arrow Articles by Dolan, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedman, H. S.
Right arrow Articles by Dolan, M. E.
Vol. 1, 943-948, September 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

O6-Benzylguanine-mediated Enhancement of Chemotherapy 1

Henry S. Friedman2, Stephen Keir, Anthony E. Pegg, Peter J. Houghton, O. Michael Colvin, Robert C. Moschel, Darell D. Bigner and M. Eileen Dolan

Departments of Surgery [H. S. F., S. K., D. D. B.], Pathology [H. S. F., D. D. B.], and Medicine [H. S. F., O. M. C., D. D. B.], Duke University Medical Center, Durham, North Carolina 27710; Department of Cellular and Molecular Physiology, The Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033 [A. E. P.]; Department of Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38101 [P. J. H.]; Laboratory of Comparative Carcinogenesis, National Cancer Institute of Frederick, Frederick, Maryland 21702 [R. C. M.]; and Department of Medicine, University of Chicago, Chicago, Illinois 60637 [M. E. D.]


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have previously demonstrated (A. E. Pegg, Cancer Res., 50: 6119–6129, 1990) that O6-benzylguanine (O6-BG) enhances nitrosourea, temozolomide, and cyclophosphamide activity in malignant glioma xenografts growing in athymic nude mice. More recently, we have demonstrated (V. J. Patel et al., Clin. Cancer Res., 6: 4154–4157, 2000; P. Pourquier et al., Cancer Res., 61: 53–58, 2001) that the combination of temozolomide plus irinotecan (CPT-11) displays a schedule-dependent enhancement of antitumor activity secondary to trapping of topoisomerase I by O6-methylguanine residues in DNA. These studies suggested that there might be favorable therapeutic interactions between O6-BG and combinations of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide or temozolomide plus CPT-11, respectively. Our present results indicate that the combination of cyclophosphamide plus BCNU plus O6-BG produces growth delays modestly-to-markedly-superior to combinations of cyclophosphamide with BCNU. Although the combination of temozolomide and CPT-11 reveals a marked increase in activity compared with either agent used alone, the addition of O6-BG to this combination dramatically increased the growth delay of the O6-alkylguanine-DNA alkyltransferase (AGT)-positive malignant glioma D-456 MG. These results suggest that a Phase I trial of CPT-11 plus temozolomide plus O6-BG in AGT-positive tumors may be an important intervention to maximize the therapeutic benefits of the combination of CPT-11 and temozolomide.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Several preclinical and clinical studies have demonstrated that the DNA repair protein AGT3 is responsible for resistance to chlorethylation or methylation damage at the O6 position of guanine in DNA (1–15), and several studies have shown that this enhances BCNU, temozolomide, and cyclophosphamide resistance. O6-BG inactivates AGT activity both in vitro and in vivo (16–27). More recently, we have demonstrated that the combination of temozolomide plus CPT-11 displays a schedule-dependent enhancement of antitumor activity secondary to the trapping of topoisomerase I by O6-methylguanine residues in DNA (28, 29). These studies suggested that there might be favorable therapeutic interactions between O6-BG, and combinations of BCNU plus cyclophosphamide or temozolomide plus CPT-11, respectively. We now report the marked increase in antitumor activity produced by these combinations after O6-BG- mediated AGT inactivation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals.
Male and female athymic BALBc mice (nu nu genotype, 6 weeks of age or older) were used for all of the studies and were maintained as described previously (30). Athymic mice were housed in an isolation facility with high-efficiency particulate air-filtration. All of the mice were maintained under a controlled 12-h light/12-h dark cycle and were provided food and water ad libitum.

Xenografts.
Human central nervous system tumor- derived xenografts were used for in vivo studies. The xenografts were maintained as described previously (31). The derivation and AGT status of these xenografts is detailed in Table 1 from a previous publication (25).


View this table:
[in this window]
[in a new window]

  		Table 1 AGT labels in CNS tumor xenografts.a

 
Drugs.
Temozolomide was provided by Schering-Plough Research Institute (Kenilworth, NJ). CPT-11 was provided by Pharmacia and Upjohn Global Distribution Center (Kalamazoo, MI). Cyclophosphamide and BCNU were purchased from Sigma (St. Louis, MO). O6-BG was synthesized as described previously (32).

s.c. Xenograft Transplantation.
s.c. tumor transplantation was performed into the right flank of the animals with an inoculation volume of 50 µl using a brei prepared from xenografts (33).

Tumor Measurements.
Tumors were measured twice weekly with hand-held vernier calipers (Scientific Products, McGraw, IL). Tumor volume was calculated according to the following formula: V = [(width)2 x (length)]/2.

Drug Toxicity.
Mice were weighed twice weekly to assess weight loss and were checked daily for survival.

Xenograft Therapy.
Groups of 10 randomly selected mice were treated when the median tumor volume was in the range of 100–500 mm3 and were compared with control animals receiving drug vehicle. Cyclophosphamide was administered via i.p. injection at a single dose of 300 mg/m2 (100 mg/kg) in 0.9% saline, which represents 22% of the LD10. BCNU was administered via i.p. injection at a single dose of 24.0 mg/m2 (8 mg/kg) in 5% ethanol, which represents 23.8% of the LD10. Temozolomide was administered via i.p. injection at a single dose of 105 mg/m2 (35 mg/kg) in 0.9% saline, which represents 10% of the LD10. CPT-11 was administered via i.p. injection at a dose of 12 mg/m2 (4 mg/kg) in 0.9% saline on days 1–5 and 8–12, which represents 10% of the LD10. O6-BG was administered at a dose of 240 mg/m2 (80 mg/kg) in polyethylene glycol-400/0.9% saline (4:6) 1 h before any of the other agents. At this dose, O6-BG depletes tumor AGT levels by >90% within 1 h.

In additional studies, groups of five non-tumor-bearing mice were treated with the combination of temozolomide at 25% of the LD10 plus CPT-11 at 25% of the LD10 given alone or with O6-BG. Similar studies with five non-tumor-bearing mice/group using temozolomide at 50% of the LD10 plus CPT-11 at 50% of the LD10 given alone or with O6-BG were also conducted.

Assessment.
The response of the s.c. xenografts was assessed by delay in tumor growth and by tumor regression. Growth delay, expressed as T - C, is defined as the difference in days between the median time required for tumors in treated (T) and control (C) animals to reach a volume five times greater than that measured at the start of treatment. Tumor regression is defined as a decrease in tumor volume over two successive measurements. Statistical analyses were performed using a personalized SAS statistical analysis program, the Wilcoxon rank order test for growth delay, and Fisher’s exact test for tumor regression as described previously (34).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Toxicity
The toxic deaths and mean nadir weight loss produced by the individual agents and their combinations in tumor-bearing mice are indicated in Tables 2 and 3. No treatment arm displayed more than one toxic death in 10 treated mice. The combination of temozolomide (0.25 LD10) plus CPT-11 (0.25 LD10), with or without O6-BG, produced no toxic deaths. The combination of temozolomide (0.50 LD10) plus CPT-11 (0.5 LD10) produced two of five deaths with O6-BG and two of five deaths without O6-BG.


View this table:
[in this window]
[in a new window]

  		Table 2 Treatment of CNS xenografts growing subcutaneously in athymic nude mice with cyclophosphamide, BCNU, and BG.

 

View this table:
[in this window]
[in a new window]

  		Table 3 Treatment of a malignant glioma xenograft in athymic nude mice with temozolomide, CPT-11, and BG.

 
Activity
Cyclophosphamide/BCNU/O6-BG.   The combination of cyclophosphamide plus O6-BG produced increased antitumor activity in five AGT-positive tumors, compared with cyclophosphamide alone (Table 2). Cyclophosphamide produced growth delays of 8.0, 12.0, 4.6, 15.3, and 16.3 days, whereas cyclophosphamide plus O6-BG produced growth delays of 9.5, 21.9, 13.1, 18, and 17.7 days against D-245 MG, D-341 MED, D-456 MG, D-528 EP, and D-612 EP, respectively. The addition of O6-BG to BCNU increased growth delays of 11.7, 1.0, 2.0, 6.5, 9.2, and 2.3 days with BCNU alone to 24.7, 20.2, 14.4, 42.5, and 45.6 days with BCNU plus O6-BG. The combination of BCNU plus cyclophosphamide produced growth delays of 23.9, 13.3, 12.0, 10.8, and 32.7 days. The use of BCNU, cyclophosphamide, and O6-BG together produced the longest growth delays of 46.6, 60.1, 70.4, 49.0, and 55.4 days.

Temozolomide/CPT-11/O6-BG.
The administration of temozolomide plus O6-BG produced an increased antitumor activity in the AGT-positive xenograft D-456 MG compared with temozolomide alone (Table 3). Temozolomide (0.1 LD10) produced growth delays of 7.9 and 2.9 days, whereas temozolomide (0.1 LD10) plus O6-BG produced growth delays of 11.3 and 7.3 days against D-456 MG. CPT-11 (0.1 LD10) produced growth delays of 23.7 and 31.1 days, with the addition of only O6-BG changing the growth delays to 26.1 and 20.4 days. The combination of temozolomide (0.1 LD10) plus CPT-11 (0.1 LD10) produced the expected marked increase in antitumor activity, with growth delays of 43.2 and 37.0 days. However, the combination of temozolomide (0.1 LD10), CPT-11 (0.1 LD10), and O6-BG produced apparent cures with growth delays of >150 and >150 days. The use of CPT-11 (1.0 LD10) or temozolomide (1.0 LD10) also produced growth delays of >150 days and >150 days.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The use of O6-BG-mediated AGT depletion to augment the antineoplastic activity of chemotherapeutic agents remains an exciting possibility. The combination of BCNU plus O6-BG, a very effective strategy in vitro and in rodents (16–24, 26, 27) has not yet produced similar results in humans, presumably because of the marked reduction of BCNU dose required to deliver this regimen safely. The dose of BCNU when given with O6-BG must be reduced by 80%, from 200 to 40 mg/m2, because of dose-limiting myelosuppression (35). The use of O6-BG plus this reduced dose of BCNU was not effective against BCNU-resistant glioblastoma multiforme (36). Nevertheless, AGT depletion is a very enticing strategy if rational and safe regimens can be designed.

The current laboratory studies focused on two different strategies to exploit O6-BG-mediated AGT depletion. BCNU and cyclophosphamide are frequently administered in combination, particularly in high-dose chemotherapy regimens using stem cell support. Our results confirm previous work in our laboratory that demonstrated modestly enhanced activity of cyclophosphamide and substantially enhanced activity of BCNU produced by O6-BG (21, 37). The concomitant use of three agents produced markedly enhanced antitumor activity, even compared with the combination of cyclophosphamide and BCNU. A precise molecular explanation for this interaction remains somewhat speculative. The interaction between BCNU and O6-BG is clearly a result of reduced removal of BCNU-induced mono-adducts with higher formation of the lethal DNA interstrand cross-link (11). The interaction between cyclophosphamide and O6-BG is more complex.

Evidence has emerged recently that suggests a role for AGT in the repair of certain cyclophosphamide-induced lesions. Cyclophosphamide is metabolized to acrolein and phosphoramide mustard. The antitumor effect is thought to be mainly mediated by interstrand cross-links formed from the reaction of phosphoramide mustard and DNA (38). We demonstrated that AGT-expressing CHO cells were significantly less sensitive to the toxic and mutagenic effects of both 4-HC (activated form of cyclophosphamide) and 4- hydroperoxydidechlorocyclophosphamide (4-HDC; a generator of acrolein and a nonalkylating form of phosphoramide mustard) than CHO cells without detectable AGT (37, 39). However, neither the toxic nor the mutagenic effects of phosphoramide mustard were altered in the presence or absence of AGT. These results suggest that inactivation of AGT by O6-BG in AGT-expressing tumors is likely to result in an increase in acrolein-induced lesions in DNA and unlikely to impact on antitumor activity produced by phosphoramide mustard. This is consistent with results shown in Table 2, in which there may be a slight advantage, albeit not dramatic, of AGT depletion (O6-BG) on tumor growth of animals treated with cyclophosphamide.

Interestingly, we observe a more dramatic tumor growth inhibition when O6-BG is combined with BCNU and cyclophosphamide. In D-245 MG, D-341 MED, and D-456 MG, the growth delay with the three-drug regimen was more than the additive effect of O6-BG with cyclophosphamide or O6-BG with BCNU. The critical toxic lesion formed in DNA by BCNU is the 1-(3-cytosinyl)-2-(1-guanyl)ethane interstrand cross-link after chloroethylation at the O6 position of guanine (40). Cyclophosphamide produces interstrand N7-N7 cross-links involving the two guanines in GNC•GNC (5'->3'/5'->3') sequences (41). We have observed that, in some cell lines deficient of AGT, O6-BG enhances the toxicity of 4-HC (42). The mechanism of enhancement is unrelated to AGT inactivation because the known toxic DNA lesions associated with nitrogen mustards occur at nucleophilic nitrogens of guanine, not the O6 position of guanine, and there is no evidence to suggest that AGT can repair these lesions. In addition, enhancement is observed in cell lines such as CHO and SQ20b (squamous cell carcinoma) that are apparently devoid of the AGT protein. 4 Preliminary results from our laboratory indicate that the formation or processing of intrastrand and/or interstrand DNA cross-links is critical for the interaction of O6-BG with cyclophosphamide (43). The dramatic growth delay when O6-BG is combined with cyclophosphamide and BCNU could be attributable to the abundance of structurally different cross-links on DNA. O6-BG might act by two mechanisms: (a) inactivation of AGT, thus producing more BCNU cross-links and (b) a more elusive mechanism involving less repair of cyclophosphamide cross-links. Both of the interstrand cross-links formed on DNA may act in concert, resulting in greater tumor growth inhibition. Nevertheless, the concomitant use of the three agents produced marked increases in antitumor activity, which suggests that translation to the clinic, presumably in a program using stem cell support to offset dose-limiting myelosuppression, may be warranted.

The striking increases in antitumor activity seen with the combination of temozolomide, CPT-11, and O6-BG are better understood and may provide a rational combination for the clinic. Temozolomide resistance is produced, at least in part, by tumor AGT (44). However, it is also possible that altered drug pharmacokinetics may be contributing to the increase in antitumor activity. A current Phase I trial of temozolomide plus O6-BG will ultimately culminate in a Phase II trial of this combination in patients with temozolomide-resistant malignant glioma. Nevertheless, it is possible that dose-limiting toxicity will, similar to the BCNU plus O6-BG trial (36), minimize the dose and potentially limit the benefit of temozolomide when given in combination with O6-BG. Accordingly, we are also conducting a Phase I trial of CPT-11 plus temozolomide designed to use methylation of the O6 position of guanine produced by temozolomide to trap topoisomerase I and enhance CPT-11 activity. Unfortunately, AGT removal of the methyl adduct may minimize any therapeutic gain if it occurs before CPT-11-induced cytotoxicity.

Therefore, although a Phase II trial of CPT-11 plus temozolomide will be warranted, a design of strategies to reduce the impact of AGT-mediated methyl adducts before CPT-11 cytotoxicity may be necessary. Our current results suggest that the use of temozolomide (to methylate tumor cell DNA), O6-BG (to prevent AGT-mediated adduct removal), and CPT-11 (to target trapped topoisomerase I) may be a highly effective clinical intervention. A Phase I trial of this three-drug regimen is currently being designed that will reflect the schedule-dependent interaction between CPT-11 and temozolomide (28) and the need to deplete AGT before temozolomide-induced methylation.


   Footnotes
 
1 This work was supported by NIH Grants NS30245 (to H. S. F.), NS20023 (to H. S. F), CA57725 (to A. E. P., H. S. F., and M. E. D.), and CA81485 (to M. E. D.). Drs. Pegg, Moschel, and Dolan have a financial relationship with Access Oncology, the company that is presently licensing O6-benzylguanine. Dr. Friedman is a paid consultant for Access Oncology. Back

2 To whom requests for reprints should be addressed, at Duke University Medical Center, Room 047, Baker House, Trent Drive, Durham, North Carolina 27710 Back

3 The abbreviations used are: AGT, O6-alkylguanine-DNA alkyltransferase; O6-BG, O6-benzylguanine; CPT-11, irinotecan; LD10, lethal dose to 10% of animals; 4-HC, 4-hydroperoxycyclophosphamide; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; CHO, Chinese hamster ovary. Back

4 Unpublished observations. Back

Received 6/ 5/02; revised 7/23/02; accepted 7/31/02.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Zlotogorski, C., and Erickson, L. C. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their activity to repair chloroethyl monoadducts.Carcinogenesis (Lond.) , 5:83 –87,1984 .[Abstract/Free Full Text]
  2. Dolan, M. E., Morimoto, K., and Pegg, A. E. Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines.Cancer Res. , 45:6413 –6417,1985a .[Medline]
  3. Dolan, M. E., Corsico, C. D., and Pegg, A. E. Exposure of HeLa cells to O6-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents.Biochem. Biophys. Res. Commun. , 132:178 –185,1985 .[CrossRef][Medline]
  4. Dolan, M. E., Young, G. S., and Pegg, A. E. Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.Cancer Res. , 46:4500 –4504,1986 .[Abstract/Free Full Text]
  5. Yarosh, D. B. The role of O6-methylguanine DNA methyltransferase in cell survival, mutagenesis and carcinogenesis.Mutat. Res. , 145:1 –16,1985 .[Medline]
  6. Yarosh, D. B., Hurst-Calderone, S., Babich, M. A., and Day, R. S., III. Initiation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base.Cancer Res. , 46:1663 –1668,1986 .[Medline]
  7. Aida, T., and Bodell, W. J. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum (II) in human glial-derived lines.Cancer Res. , 47:1361 –1366,1987 .[Abstract/Free Full Text]
  8. Aida, T., Cheitlin, R. A., and Bodell, W. J. Inhibition of O6-alkylguanine-DNA alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.Carcinogenesis (Lond.) , 8:1219 –1223,1987 .[Abstract/Free Full Text]
  9. Dolan, M. E., Larkin, G. L., English, H. F., and Pegg, A. E. Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.Cancer Chemother. Pharmacol. , 25:103 –108,1989 .[CrossRef][Medline]
  10. Schold, S. C., Jr., Brent, T. P. von Hofe, E., Friedman, H. S., Mitra, S., Bigner, D. D., Swenberg, J. A., and Kleihues, P. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain tumor xenografts.J. Neurosurg. , 70:573 –577,1989 .[Medline]
  11. Pegg, A. E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.Cancer Res. , 50:6119 –6129,1990 .[Free Full Text]
  12. Ludlum, D. B. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal.Mutat. Res. , 233:117 –126,1990 .[CrossRef][Medline]
  13. Pegg, A. E., and Byers, T, Repair of DNA containing O6-alkylguanine.FASEB J. , 6:2302 –2310,1992 .[Abstract]
  14. Mitra, S., and Kaina, B. Regulation of repair of alkylation damage in mammalian genomes.Prog. Nucleic Acid Res. Mol. Biol. , 44:109 –142,1993 .[Medline]
  15. Pegg, A. E., Dolan, M. E., and Moschel, R. C. Structure, function and inhibition of O6-alkylguanine-DNA alkyltransferase.Prog. Nucleic Acid Res. Mol. Biol. , 51:167 –223,1995 .[Medline]
  16. Gerson, S. L., Trey, J. E., and Miller, K. Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase.Cancer Res. , 48:1521 –1527,1988 .[Abstract/Free Full Text]
  17. Dolan, M. E., Moschel, R. C., and Pegg, A. E. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.Proc. Natl. Acad. Sci. USA , 87:5368 –5372,1990a .[Abstract/Free Full Text]
  18. Dolan, M. E., Stine, L., Mitchell, R. B., Moschel, R. C., and Pegg, A. E. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.Cancer Commun. , 2:371 –377,1990b .[Medline]
  19. Dolan, M. E., Pegg, A. E., Dumenco, L. L., Moschel, R. C., and Gerson, S. L. Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine and O6-methylguanine.Carcinogenesis (Lond.) , 12:2305 –2309,1991 .[Abstract/Free Full Text]
  20. Dolan, M. E., Mitchell, R. B., Mummert, C., Moschel, R. C., and Pegg, A. E. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.Cancer Res. , 51:3367 –3372,1991 .[Abstract/Free Full Text]
  21. Friedman, H. S., Dolan, M. E., Moschel, R. C., Pegg, A. E., Felker, G. M., Rich, J., Bigner, D. D., and Schold, S. C. Jr. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.J. Natl. Cancer Inst. (Bethesda) , 84:1926 –1931,1992 .[Abstract/Free Full Text]
  22. Mitchell, R. B., Moschel, R. C., and Dolan, M. E. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.Cancer Res. , 52:1171 –1175,1992 .[Abstract/Free Full Text]
  23. Felker, G. M., Friedman, H. S., Dolan, M. E., Moschel, R. C., and Schold, S. C. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.Cancer Chemother. Pharmacol. , 32:471 –476,1993 .[CrossRef][Medline]
  24. Pegg, A. E., Boosalis, M., Samson, L., Moschel, R. C., Byers, T. L, Swenn, K., and Dolan, M. E. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine.Biochemistry , 32:11998 –12006,1993 .[CrossRef][Medline]
  25. Friedman, H. S., Dolan, M. E., Pegg, A. E., Marcelli, S. Keir, S. Catino, J. J., Bigner, D. D., and Schold, S. C. Activity of temozolomide with or without O6-benzylguanine in the treatment of central nervous system tumor xenografts.Cancer Res. , 55:2853 –2857,1995 .[Abstract/Free Full Text]
  26. Dolan, M. E., and Pegg, A. E. O6-Benzylguanine and its role in chemotherapy.Clin. Cancer Res. , 8:837 –847,1997 .
  27. Friedman, H. S., Kokkinakis, D. M., Pluda, J., Friedman, A. H., Cokgor, I., Haglund, M. M., Ashley, D. M., Rich, J., Dolan, M. E., Pegg, A. E., Moschel, R. C., McLendon, R. E., Kerby, T., Herndon, J., Bigner, D. D., and Schold, S. C. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.J. Clin. Oncol. , 16:3570 –3575,1998a .[Abstract]
  28. Patel, V. J., Elion, G. B., Houghton, P. J., Keir, S., Pegg, A. E., Johnson, S. P., Dolan, M. E., Bigner, D. D., and Friedman, H. S. Schedule dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.Clin. Cancer Res. , 6:4154 –4157,2000 .[Abstract/Free Full Text]
  29. Pourquier, P., Waltman, J. L, Urasaki, Y., Loktionova, N. A., Pegg, A. E., Nitiss, J. L., and Pommier, Y. Topoisomearse I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.Cancer Res. , 61:53 –58,2001 .[Abstract/Free Full Text]
  30. Bullard, D. E., and Bigner, D. D. The heterotransplantation of human carniopharyngiomas in athymic "nude" mice.Neurosurgery , 4:308 –314,1979 .[Medline]
  31. Friedman, H. S., Houghton, P. J., Schold, S. C., Keir, S., and Bigner, D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.Cancer Chemother. Pharmacol. , 34:171 –174,1994 .[Medline]
  32. Dolan, M. E., Moschel, R. C., and Pegg, A. E. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.Proc. Natl. Acad. Sci. USA , 87:5368 –5372,1990 .
  33. Friedman, H. S., Colvin, O. M., Skapek, S. X., Ludeman, S. M., Elion, G. B., Schold, S. C., Jr., Jacobsen, P. F., Muhlbaier, L. H., and Bigner, D. D. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.Cancer Res. , 48:4189 –4195,1988 .[Abstract/Free Full Text]
  34. Friedman, H. S., Schold, S. C., Jr., and Bigner, D. D. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.Cancer Res. , 46:224 –228,1986 .[Abstract/Free Full Text]
  35. Friedman, H. S., Pluda, J., Quinn, J. A., Ewesuedo, R. B., Long, L., Friedman, A. H., Cokgor, I., Colvin, O. M., Haglund, M. M., Ashley, D. M., Rich, J. R., Sampson, J., Pegg, A. E., Moschel, R. C., McLendon, R. E., Provenzale, J. M., Stewart, E. S., Tourt-Uhlig, S., Garcia-Turner, A. M., Herndon, J. E., II, Bigner, D. D., and Dolan, M. E. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.J. Clin. Oncol. , 18:3522 –3528,2000 .[Abstract/Free Full Text]
  36. Quinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., Haglund, M., Pegg, A. E., Moschel, R. C., McLendon, R. E., Provenzale, J. M., Gururangan, S., Tourt-Uhlig, S., Herndon, J. E., II, Bigner, D. D., and Friedman, H. S. Phase 2 trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.J. Clin. Oncol. , 20:2277 –2283,2002 .[Abstract/Free Full Text]
  37. Friedman, H. S., Pegg, A. E., Johnson, S. P., Loktionova, N. A., Dolan, M. E., Modrich, P., Moschel, R. C., Struck, R., Brent, T. P., Ludeman, S., Bullock, N., Kilborn, C., Keir, S., Dong, Q., Bigner, D. D., and Colvin, O. M. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.Cancer Chemother. Pharmacol. , 43:80 –85,1999 .[CrossRef][Medline]
  38. Colvin, O. M. An overview of cyclophosphamide development and clinical applications.Curr. Pharm. Des. , 5:555 –560,1999 .[Medline]
  39. Cai, Y., Wu, M. H., Ludeman, S. M., Grdina, D. J., and Dolan, M. E. Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.Cancer Res. , 59:3059 –3063,1999 .[Abstract/Free Full Text]
  40. Kohn, K. W. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas.Cancer Res , 37:1450 –1454,1977 .[Abstract/Free Full Text]
  41. Dong, Q., Barsky, D., Colvin, M. E., Melius, C. F., Ludeman, S. M., Moravek, J. F., Colvin, O. M., Bigner, D. D., Modrich, P., and Friedman, H. S. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).Proc. Natl. Acad. Sci. USA , 92:12170 –12174,1995 .[Abstract/Free Full Text]
  42. Cai, Y., Ludeman, S. M., Wilson, L. R., Chung, A. B., and Dolan, M. E. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells.Mol. Cancer Ther. , 1:21 –28,2001 .[Abstract/Free Full Text]
  43. Fishel, M. L., Connell, P., Siddiqui, N., and Dolan, M. E. Effect of O6-benzylguanine on nitrogen mustard and cisplatin induced toxicity in head and neck cancer cells.Proc. Am. Assoc. Cancer Res. , 43:794 ,2002 .
  44. Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F., Semen, A. J., Cokgor, I., Rich, J., Stewart, E., Colvin, O. M., Provenzale, J. M., Bigner, D. D., Haglund, M. M., Friedman, A. H., and Modrich, P. L. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.J. Clin. Oncol. , 16:3851 –3857,1998 .[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al.
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
Clin. Cancer Res., November 15, 2007; 13(22): 6712 - 6718.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. Wagner, R. E. McLendon, K. J. Yoon, B. D. Weiss, C. A. Billups, and M. K. Danks
Targeting Methylguanine-DNA Methyltransferase in the Treatment of Neuroblastoma
Clin. Cancer Res., September 15, 2007; 13(18): 5418 - 5425.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. Gururangan, M. J. Fisher, J. C. Allen, J. E. Herndon II, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, P. C. Phillips, M. A. Watral, et al.
Temozolomide in Children with progressive low-grade glioma
Neuro-oncol, April 1, 2007; 9(2): 161 - 168.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung
Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
J. Clin. Oncol., November 20, 2006; 24(33): 5271 - 5276.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Fruehauf, H. Brem, S. Brem, A. Sloan, G. Barger, W. Huang, and R. Parker
In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas
Clin. Cancer Res., August 1, 2006; 12(15): 4523 - 4532.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Ueno, S. H. Ko, E. Grubbs, Y. Yoshimoto, C. Augustine, Z. Abdel-Wahab, T.-Y. Cheng, O. I. Abdel-Wahab, S. K. Pruitt, H. S. Friedman, et al.
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Mol. Cancer Ther., March 1, 2006; 5(3): 732 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ranson, M. R. Middleton, J. Bridgewater, S. M. Lee, M. Dawson, D. Jowle, G. Halbert, S. Waller, H. McGrath, L. Gumbrell, et al.
Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors
Clin. Cancer Res., March 1, 2006; 12(5): 1577 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Ko, T. Ueno, Y. Yoshimoto, J. S. Yoo, O. I. Abdel-Wahab, Z. Abdel-Wahab, E. Chu, S. K. Pruitt, H. S. Friedman, M. W. Dewhirst, et al.
Optimizing a Novel Regional Chemotherapeutic Agent against Melanoma: Hyperthermia-Induced Enhancement of Temozolomide Cytotoxicity
Clin. Cancer Res., January 1, 2006; 12(1): 289 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. Hidaka, Y. Takagi, T. Y. Takano, and M. Sekiguchi
PCNA-MutS{alpha}-mediated binding of MutL{alpha} to replicative DNA with mismatched bases to induce apoptosis in human cells
Nucleic Acids Res., October 4, 2005; 33(17): 5703 - 5712.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. N. Trivedi, K. H. Almeida, J. L. Fornsaglio, S. Schamus, and R. W. Sobol
The Role of Base Excision Repair in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death
Cancer Res., July 15, 2005; 65(14): 6394 - 6400.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Bobola, J. R. Silber, R. G. Ellenbogen, J. R. Geyer, A. Blank, and R. D. Goff
O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines
Clin. Cancer Res., April 1, 2005; 11(7): 2747 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. Wagner, K. R. Crews, L. C. Iacono, P. J. Houghton, C. E. Fuller, M. B. McCarville, R. E. Goldsby, K. Albritton, C. F. Stewart, and V. M. Santana
Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors
Clin. Cancer Res., February 1, 2004; 10(3): 840 - 848.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. Yanamadala and M. Ljungman
Potential Role of MLH1 in the Induction of p53 and Apoptosis by Blocking Transcription on Damaged DNA Templates
Mol. Cancer Res., August 1, 2003; 1(10): 747 - 754.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedman, H. S.
Right arrow Articles by Dolan, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedman, H. S.
Right arrow Articles by Dolan, M. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online